Researchers have mapped the relationship between length of pregnancy and chemical DNA changes in more than 6,000 newborn babies. For each week's longer pregnancy, DNA methylation changes in thousands of genes were detected in the umbilical cord blood. The study is published in Genome Medicine.
The US Food and Drug Administration late on Friday authorized marketing of Asuragen’s AmplideX Fragile X Dx and Carrier Screen Kit, the first genetic test for fragile X syndrome (FXS).
Scientists show for the first time that a newer type of CRISPR, called base-editing, can safely cure cystic fibrosis in stem cells derived from patients.
Traditional cardiovascular risk factors often assessed in an annual physical, such as blood pressure, cholesterol levels, diabetes, and smoking status, are at least as valuable in predicting who will develop coronary heart disease (CHD) as a sophisticated genetic test that surveys millions of different points in DNA, a study led by a UT Southwestern Medical Center researcher suggests. The findings, published Feb. 18, 2020, in JAMA, support the utility of these tried-and-true methods.
Higher maternal blood pressure in pregnancy is associated with chemical modifications to placental genes, according to a study by researchers from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health (NIH). The changes involve DNA methylation, the binding of compounds known as methyl groups to DNA, which can alter a gene's activity. Exposure to high blood pressure in the womb increases the risk for impaired fetal growth and the risk for cardiovascular disease in adult life. Ultimately, the findings could yield information on the earliest origins of cardiovascular disease and how to prevent it from occurring.
